Washington University School of Medicine – Polycythemia vera

Access Program Information

<p><strong>Chuvash polycythemia (CP)</strong>, <span id=”form-widgets-disease-0-wrapper” class=”option”><span class=”label”>also called&nbsp; <strong>Polycythemia vera</strong></span></span> or <strong>Chuvash erythomatosis</strong>, is a rare form of congenital polycythemia caused by mutations in the VHL gene. Currently, there are no therapies that have proven effective for CP. Recent studies have demonstrated that VHL (<em>von Hippel-Lindau tumor suppressor)</em> regulates the activity of JAK2 (Janus kinase 2). In mouse models, inhibition of JAK2 reverses the CP phenotype. Therefore, the investigators hypothesize that JAK2 inhibition may have significant clinical benefits for CP patients.</p>

Rare Disease: